The Company maintains the Option Plan whereby certain key officers, directors and consultants may be granted stock options for common shares of the Company. The maximum number of common shares that are issuable under the Option Plan is limited to 185,133 common shares. Under the Option Plan, the exercise price of each option may not be lower than the greater of the closing price of the Company’s shares on the trading day prior to the grant date or the grant date itself, whichever is higher. Vesting of options is determined at the discretion of the Board. As at December 31, 2025, the Company had 118,996 common shares available for issuance under the Option Plan.

The following summarizes the stock option activity for the six months ended December 31, 2025, and the year ended June 30, 2025:

 Schedule of stock option activity

Option activities for the six months ended December 31, 2025

On July 21, 2025, the Board of Directors approved the repricing of all outstanding stock options to a revised exercise price of US $5.00 per option. The repricing applied to all option holders on a consistent basis. Management assessed the impact of the repricing and determined that the revised exercise price did not result in any incremental fair value being conveyed to option holders. Accordingly, no additional share-based payment expense has been recognized in relation to this repricing.

On July 21, 2025, the Company granted 4,000 options to a director. The options are exercisable at a price of US $5.00 per common share until January 30, 2028 and vested immediately on grant. The options were valued using Black-Scholes with the following assumptions: expected volatility of 422.48%, expected dividend yield of 0%, risk-free interest rate of 2.81%, and an expected life of 2.53 years. The grant date fair value attributable to these options of $23,095 was recorded as stock-based compensation.

Option activities for the year ended June 30, 2025

On January 9, 2025, the Board of Directors approved the repricing of all outstanding stock options to a revised exercise price of US $19.50 per option (subsequently repriced to US $5.00). The repricing applied to all option holders on a consistent basis. Management assessed the impact of the repricing and determined that the revised exercise price did not result in any incremental fair value being conveyed to option holders. Accordingly, no additional share-based payment expense has been recognized in relation to this repricing.

The following table summarizes information of stock options outstanding and exercisable as at December 31, 2025:

 Schedule of stock options outstanding and exercisable